NZZ Equity Biotech Day - Partners 2012

We thank our partners for supporting the "NZZ Equity" Biotech Day 2012.
In Cooporation with
SIX Swiss Exchange

Europe’s leading exchange for life science companies

With a public offering of securities in Switzerland, and thanks to the strong placing power afforded by the Swiss-based investment banks, life science companies gain access to a sector specific experienced, highly competent and broadly international circle of investors. In Europe, SIX Swiss Exchange has grown to become the most important securities exchange in terms of the total market capitalisation of listed life sciences companies.

Swiss Biotech Association
Swiss Biotech Association (SBA) was founded in March 1998. Today more than 200 companies represent this growing association. SBA is the industry association of small and medium-sized enterprises active in all areas of biotechnology but also a very good networking platform for the multinational companies active in the sector. The membership is open to companies of various size concerned with different aspects of modern biotechnology such as R&D, production, marketing and sales, finance, services and consulting. Activities of member companies span different sectors of biotechnology including pharmaceuticals, diagnostics, agriculture, fod, environmental biotechnology, and specialty chemicals. The SBA is also managing the national Cluster for Biotechnology where the Swiss Life Science regions the finance market (SIX) and the industry work together to promote Switzerland as a key Biotech country.
Steering Committee of the Swiss Biotech Report 2012
The Swiss Biotech Report 2012 is published by the Steering Committee members: Domenico Alexakis, Swiss Biotech Association, Zurich, Oreste Ghisalba, CTI, Berne, Andrea Isler, SIX Swiss Exchange AG, Zurich, Heinz Müller, Swiss Federal Institute of Intellectual Property, Berne, Antje Runschke, Osec, Zurich and Jürg Zürcher, Ernst & Young Ltd., Basel. Further project partners are the Swiss National Fund, the national competence network for biotechnology biotechnet Switzerland, the Swiss technology Transfer Association swiTT, BaselArea, the BerneCapital Area, BioAlps, Biopolo Ticino and the Greater Zurich Area. The Swiss Biotech Report 2012 can be downloaded from the website www.swissbiotechreport.ch as of April 3, 2012.
Premium Partners
Deloitte
Deloitte provides audit, tax, consulting and corporate finance services to public and private clients spanning multiple industries. With a globally connected network of member firms in 140 countries, Deloitte brings world class capabilities and deep local expertise to help clients succeed wherever they operate In Switzerland over 830 employees provide support to our clients – globally, 169,000 employees are committed to our clients.
The Deloitte Life Sciences and Biotech Industry group, made up of the Life Sciences specialists from member firms, is comprised of more than 4,800 professionals in over 50 countries. Their understanding of the industry’s challenges and their ability to quickly respond with integrated and comprehensive services put the Deloitte member firms in a unique position to help our clients. From inception of a company, to an initial public offering or a global product launch, our professionals have the comprehensive experience that life sciences and biotech companies demand to address the assurance, tax and consulting needs of their business.
CTI Innovation Promotion Agency

„Science to market“. That is the central idea behind the CTI Innovation Promotion Agency’s support for research-based innovation projects carried out by businesses together with universities. It offers to promote innovation, in addition to providing coaching, knowledge-transfer and training for SMEs as well as for start-ups.

Partners
Merck Serono
Merck Serono is the division for innovative prescription pharmaceuticals of Merck KGaA, Darmstadt, Germany, a global pharmaceutical and chemical company. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and markets innovative small molecules and biopharmaceuticals to help patients with unmet medical needs. In the United States and Canada, EMD Serono operates through separately incorporated affiliates. Merck Serono has leading brands serving patients with cancer (Erbitux®, cetuximab), multiple sclerosis (Rebif®, interferon beta-1a), infertility (Gonal-f®, follitropin alfa), endocrine and metabolic disorders (Saizen® and Serostim®, somatropin), (Kuvan®, sapropterin dihydrochloride) as well as cardiometabolic diseases (Glucophage®, metformin), (Concor®, bisoprolol), (Euthyrox®, levothyroxine). Not all products are available in all markets. With an annual R&D expenditure of around € 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic areas including neurodegenerative diseases, oncology, fertility and endocrinology, as well as new areas potentially arising out of research and development in autoimmune and inflammatory diseases.
Legal Partner
VISCHER Attorneys at Law
VISCHER is one of the major independent Swiss law firms. VISCHER has extensive experience in advising both Swiss and international biotech companies in sector specific legal matters, including merger and acquisition, financing, partnering, research & development arrangements, commercial agreements, and regulatory matters.
Attendant Experts
Biogen Idec International GmbH
Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates more than $5 billion in annual revenues.
Janssen-Cilag AG

Janssen is a leading research-based pharmaceutical company with over 20,000 employees worldwide and operations in over 50 countries. The Swiss office is based in Baar and employs around 100 people. Janssen has developed more than 80 drugs with some ground-breaking agents. The WHO has added five drugs from Janssen to the list of essential medicines. Janssen’s research is divided in four areas of competence: pain / internal medicine, central nervous system, biotechnology and virology.

F. Hoffmann-La Roche Ltd
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80’000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com:
Media and Communication Partners
SECA
The Swiss Private Equity & Corporate Finance Association (SECA) is the representative body for Switzerland‘s private equity, venture capital and corporate finance industries. SECA has the objective to promote private equity and corporate finance activities in Switzerland.
Private Equity refers to equity investments in privately held, non-quoted companies ("Beteiligungsfinanzierungen"). Corporate Finance Services are advisory services related to mergers, acquisitions, buyouts and the financing of companies.
Venture Valuation
Venture Valuation specializes in independent assessments and valuations of companies in high-growth markets, such as biotechnology, life sciences and medical technology. Clients include investors as well as companies for financing rounds, licensing deals or fairness opinions. Venture Valuation recently did the fairness opinion for the reverse merger of Arpida and Evolva. Further more, the company also provides information services like the global Biotech Database (www.biotechgate.com) around the world for clients like BioteCANADA, BioCom San Diego, Swiss Stock Exchange SIX, Swiss Biotech, Basel Area, BioAlps, Biopolo, Medicon Valley, Life Sciences Health (Netherlands) and over 25 country databases.
CTI Invest
CTI Invest is a platform where high-tech companies can find early and later stage capital. The deal flow originates out of the Swiss CTI Startup coaching program, out of the portfolio of our investor members or can even be external companies (against a service fee). In addition to the live presentation at the events, the companies can present themselves to the investors through video podcasting.